---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-052891"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-10-11T23:59:59+00:00"
generated_at: "2026-06-10T01:35:36.595449+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma shareholders elect directors, ratify auditor, approve exec comp at annual meeting

## Summary
- Five director nominees elected with >97% votes for each; non-votes ~1.27M.
- Ernst & Young LLP appointed as auditor with 97.65% votes for (3,982,999 for).
- Advisory vote on executive compensation approved with 97.24% votes for (2,730,102 for).
- Shareholder turnout 54.76% (4,078,661 votes of 7,448,033 outstanding shares).
- Meeting held Oct 10, 2023; proxy solicitation unopposed.

## SEC filing metadata
- accession: 0000950170-23-052891
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-10-11T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023052891/0000950170-23-052891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023052891/acst-20231010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-052891
- JSON: https://secwatch.observer/filing/0000950170-23-052891.json
- Plain text: https://secwatch.observer/filing/0000950170-23-052891.txt

## Key facts
- Shareholder Votes
  Grace Therapeutics, Inc. shareholders approved Election of Directors at the 2023-10-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-10-10
  source text: Proposal No. 1 – Election of Directors The following nominees were elected as directors by the votes indicated to serve until the Company’s next annual meeting of shareholders, as set forth in the Proxy Statement: Nominee Votes For % Votes For Withheld % Votes Withheld Non-Vote Vimal Kavuru 2,746,424 97.82% 61,122 2.18% 1,271,115 A. Brian Davis 2,761,502 98.36% 46,044 1.64% 1,271,115 S. George Kottayil 2,758,885 98.27% 48,662 1.73% 1,271,115 Prashant Kohli 2,758,939 98.27% 48,607 1.73% 1,271,115 Edward Neugeboren 2,759,075 98.27% 48,471 1.73% 1,271,115
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023052891/0000950170-23-052891-index.htm
- Shareholder Votes
  Grace Therapeutics, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2023-10-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-10-10
  source text: Proposal No. 3 – Advisory Vote to Approve Named Executive Officer Compensation The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as described in the Proxy Statement was approved by the shareholders by the following vote: For % For Against % Against Abstain % Abstain Non-Vote 2,730,102 97.24% 68,055 2.42% 9,389 0.33% 1,271,115
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023052891/0000950170-23-052891-index.htm
- Shareholder Votes
  Grace Therapeutics, Inc. shareholders approved Appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm at the 2023-10-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-10-10
  source text: Proposal No. 2 – Appointment of Ernst & Young LLP The proposal to appoint Ernst & Young LLP as the Company’s independent registered public accounting firm until the close of the Company’s next annual meeting shareholders and to authorize the Company’s board of directors to fix their remuneration was approved by the shareholders by the following vote: For % For Against % Against Abstain % Abstain Non-Vote 3,982,999 97.65% 81,017 1.99% 14,644 0.36% 1
  evidence_url: https://www.sec.gov/Archives/edgar/data/1444192/000095017023052891/0000950170-23-052891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.